Wedbush Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price

Biogen (NASDAQ:BIIB) had its price objective upped by Wedbush from $201.00 to $215.00 in a research report report published on Thursday,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

A number of other research analysts have also recently issued reports on the company. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Jefferies Financial Group reiterated a “buy” rating on shares of Biogen in a research report on Monday, July 13th. HSBC reissued a “reduce” rating and set a $157.00 price target on shares of Biogen in a report on Monday, July 6th. Guggenheim upped their price objective on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Finally, Morgan Stanley decreased their price objective on shares of Biogen from $224.00 to $222.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Biogen currently has a consensus rating of “Moderate Buy” and a consensus target price of $223.36.

Biogen Stock Down 0.6%

NASDAQ BIIB opened at $207.93 on Thursday. Biogen has a 1-year low of $124.56 and a 1-year high of $219.72. The company has a market capitalization of $30.70 billion, a price-to-earnings ratio of 36.80 and a beta of 0.16. The stock’s 50 day moving average is $201.05 and its two-hundred day moving average is $190.52. The company has a current ratio of 1.87, a quick ratio of 2.41 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.Biogen’s revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts forecast that Biogen will post 12.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Reflection Asset Management acquired a new stake in Biogen in the 4th quarter valued at about $25,000. WPG Advisers LLC increased its holdings in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Biogen in the fourth quarter valued at approximately $30,000. WFA of San Diego LLC bought a new position in Biogen in the 2nd quarter worth approximately $32,000. Finally, Root Financial Partners LLC raised its position in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 123 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q2 results exceeded expectations: Biogen reported approximately $2.74 billion in revenue, up 3.4% year over year and above the $2.46 billion consensus estimate. Adjusted EPS of $3.60 also topped forecasts near $2.94, supported by stronger rare-disease and newer-product sales. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: Growth portfolio is offsetting legacy weakness: Revenue from Biogen’s Growth Portfolio rose 24% to about $1.06 billion, surpassing its legacy multiple sclerosis portfolio. The Apellis acquisition added sales from SYFOVRE and EMPAVELI, while products including SKYCLARYS and ZURZUVAE contributed to momentum. Biogen’s Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
• Positive Sentiment: Analyst sentiment improved: TD Cowen raised its price target to $225 and assigned a Buy rating, while Morgan Stanley lifted its target to $231 and maintained Equal Weight. Wedbush also raised its target to $215, and Piper Sandler reaffirmed its Buy rating. Analyst target updates
• Neutral Sentiment: 2026 outlook was updated: Biogen expects full-year non-GAAP EPS of $12 to $13 and mid-single-digit revenue growth. The revenue outlook benefits from the newer portfolio, but the EPS range is below the roughly $13.45 analyst consensus, partly reflecting acquisition-related costs. Biogen beats quarterly estimates as newer drugs fuel growth
• Negative Sentiment: Reported profitability deteriorated materially: GAAP net income fell to $97.5 million from $634.8 million a year earlier, while diluted EPS dropped to $0.66 from $4.33. Legacy multiple sclerosis sales also remained under pressure, and Leqembi sales narrowly missed expectations. Biogen profitability compression

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.